Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Number of holders
-
84
-
Total 13F shares, excl. options
-
64,980,785
-
Shares change
-
-7,799,480
-
Total reported value, excl. options
-
$102,682,821
-
Value change
-
-$12,116,491
-
Put/Call ratio
-
6.7%
-
Number of buys
-
30
-
Number of sells
-
-51
-
Price
-
$1.58
Significant Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q2 2022
117 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common shares as of Q2 2022.
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64,980,785 shares
of 250,425,788 outstanding shares and own 26% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34,935,485 shares), VANGUARD GROUP INC (5,951,493 shares), Defender Capital, LLC. (5,131,935 shares), BlackRock Inc. (3,755,757 shares), Laurion Capital Management LP (2,422,367 shares), RAFFLES ASSOCIATES LP (1,930,536 shares), Prescott General Partners LLC (1,851,851 shares), JPMORGAN CHASE & CO (1,256,731 shares), GEODE CAPITAL MANAGEMENT, LLC (1,249,372 shares), and MILLENNIUM MANAGEMENT LLC (1,020,446 shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.